A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation

ConclusionsLusutrombopag 3  mg once daily for 7 days was effective without raising concerns about excessive increases in platelet count.Clinical trial registrationThe study is registered at JapicCTI-121944.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research